The negativity was perfectly summed up by BTIG analyst Janine Stichter ... now is the time for investors to consider an entry into the stock. NIKE Inc. is a leading developer, designer, marketer ...

Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

In a report released yesterday, Andre Madrid from BTIG reiterated a Buy rating on AeroVironment (AVAV – Research Report), with a price target of $225.00. The company’s shares closed yesterday ...

Tuesday, Apollo Commercial Real Estate Finance (NYSE:ARI), currently trading at $9.09 with a market capitalization of $1.26 billion, maintained a Neutral stock rating from BTIG following the ...

On Tuesday, BTIG analyst Thomas Catherwood maintained a Neutral rating on shares of Kilroy Realty Corporation (NYSE:KRC), following the company's release of its fourth-quarter 2024 financial results.

In a report released yesterday, Andrew Harte from BTIG maintained a Hold rating on Global Payments (GPN – Research Report). The company’s shares closed last Friday at $109.60. Leverage the ...

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial ...

On Monday, BTIG initiated coverage on ARMOUR Residential (NYSE:ARR) with a Neutral rating. The firm's analysis suggests a potential for a 20%+ total return, factoring in a steady 15% dividend yield ...

On Monday, BTIG analyst Andrew Harte maintained a Neutral rating on Global Payments Inc. (NYSE:GPN) stock, despite an approximate 11% increase in share value since the company's third-quarter 2024 ...

BTIG Research analyst C. Reichardt now forecasts that the construction company will earn $1.73 per share for the quarter, down from their prior estimate of $1.79. Skip to main content Analyst Ratings ...